What's Happening?
The cell and gene therapy contract development and manufacturing organization (CDMO) market is projected to grow significantly, reaching USD 74.03 billion by 2034. The market is expected to expand at a compound
annual growth rate (CAGR) of 27.92% from 2025 to 2034. North America currently dominates the market, while the Asia Pacific region is anticipated to experience the fastest growth. Key segments driving this growth include oncology and rare diseases, with cell therapy leading the product type category.
Why It's Important?
The rapid growth of the cell and gene therapy CDMO market underscores the increasing demand for advanced therapeutic solutions in the healthcare industry. This expansion reflects the broader trend towards personalized medicine and the development of targeted therapies for complex diseases. The market's growth is likely to attract significant investment and innovation, potentially leading to breakthroughs in treatment options for cancer, rare diseases, and other conditions. For biopharmaceutical companies, this represents an opportunity to leverage CDMO services to accelerate drug development and bring new therapies to market more efficiently.
